Abonnement à la biblothèque: Guest
Portail numérique Bibliothèque numérique eBooks Revues Références et comptes rendus Collections
Critical Reviews™ in Therapeutic Drug Carrier Systems
Facteur d'impact: 2.9 Facteur d'impact sur 5 ans: 3.72 SJR: 0.736 SNIP: 0.818 CiteScore™: 4.6

ISSN Imprimer: 0743-4863
ISSN En ligne: 2162-660X

Volumes:
Volume 37, 2020 Volume 36, 2019 Volume 35, 2018 Volume 34, 2017 Volume 33, 2016 Volume 32, 2015 Volume 31, 2014 Volume 30, 2013 Volume 29, 2012 Volume 28, 2011 Volume 27, 2010 Volume 26, 2009 Volume 25, 2008 Volume 24, 2007 Volume 23, 2006 Volume 22, 2005 Volume 21, 2004 Volume 20, 2003 Volume 19, 2002 Volume 18, 2001 Volume 17, 2000 Volume 16, 1999 Volume 15, 1998 Volume 14, 1997 Volume 13, 1996 Volume 12, 1995

Critical Reviews™ in Therapeutic Drug Carrier Systems

DOI: 10.1615/CritRevTherDrugCarrierSyst.2013005684
pages 277-291

Particulate Pulmonary Delivery Systems Containing Anti-Tuberculosis Agents

Anuradha Gupta
CSIR Central Drug Research Institute, Lucknow 226001, India
Sanketkumar M. Pandya
CSIR Central Drug Research Institute, Lucknow 226001, India
Imran Mohammad
CSIR Central Drug Research Institute, Lucknow 226001, India
Atul Kumar Agrawal
CSIR Central Drug Research Institute, Lucknow 226001, India
Mradul Mohan
CSIR Central Drug Research Institute, Lucknow 226001, India
Amit Misra
CSIR Central Drug Research Institute, Lucknow 226001, India

RÉSUMÉ

There is renewed interest in delivering anti-tuberculosis (TB) drugs to the lungs by inhalation. Several groups have investigated particulate pulmonary drug delivery formulations containing anti-TB agents, prepared using a variety of design approaches and processes. This review summarizes trends that indicate feasibility and translation of research efforts aimed at developing inhaled therapies for TB. Whereas formulations intended for reconstitution as solutions prior to nebulization can be produced with relative ease, particle engineering for powder formulations is more specialized. Spray drying and emulsion methods used to prepare particulate pulmonary delivery systems of anti-TB agents are compared. Pharmaceutical characterization is outlined. Administration of repeated inhalations to laboratory animals, especially under Animal Biosafety Level-3 (ABSL-3) containment as required for TB research, is another major challenge. Techniques employed by different groups are reviewed in the context of suitability for drug delivery and amenability towards use in ABSL-3 settings. It is concluded that spray drying is suitable for production of inhalable particles, rigorous physicochemical characterization is necessary for developing inhaled therapies as drug products, and pulmonary delivery of formulations containing anti-TB drugs to animals infected with Mycobacterium tuberculosis can best be carried out using handheld devices.


Articles with similar content:

Current Nanotechnological Strategies for Effective Delivery of Bioactive Drug Molecules in the Treatment of Tuberculosis
Critical Reviews™ in Therapeutic Drug Carrier Systems, Vol.31, 2014, issue 1
Mandeep Kaur, Goutam Rath, Tarun Garg, Amit Kumar Goyal
Pulmonary Drug Delivery Systems: Recent Developments and Prospects
Critical Reviews™ in Therapeutic Drug Carrier Systems, Vol.19, 2002, issue 4-5
Th. F. Vandamme, N. Butz, H. M. Courrier
Evaluation of Nanocarrier-Based Dry Powder Formulations for Inhalation with Special Reference to Anti-Tuberculosis Drugs
Critical Reviews™ in Therapeutic Drug Carrier Systems, Vol.36, 2019, issue 3
Pravin K. Shende, Shirish Deshpande, Ashwini Deshpande, Tulshidas S. Patil, Ram Gaud
Reversible Skin Permeabilization for Transdermal Delivery of Macromolecules
Critical Reviews™ in Therapeutic Drug Carrier Systems, Vol.14, 1997, issue 4
Mark R. Prausnitz
The Role of Surface Functionalization in the Design of PLGA Micro- and Nanoparticles
Critical Reviews™ in Therapeutic Drug Carrier Systems, Vol.27, 2010, issue 1
Michael Wirth, Vera Kerleta, Christian Fillafer, Franz Gabor, Gerda Ratzinger